Pharmacological importance of stereochemical resolution of enantiomeric drugs

Drug Safety

Volumn 17, Issue 3, 1997, Pages 149-165

  Islam, Mohamed R ^a   Mahdi, Jassem G ^a   Bowen, Ivor D ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN;

DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG PURITY; ENANTIOMER; PRIORITY JOURNAL; RACEMIC MIXTURE; REVIEW; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 0030792741     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717030-00002     Document Type: Review

References (135)

1. De Camp WH. FDA perspective on the development of new stereoisomeric drugs: chemistry, manufacturing and control issues. In: Wainer IW, editor. Drug stereochemistry: analytical methods and pharmacology. 2nd ed. New York: Marcel Decker, Inc., 1993: 365-84
2. Rauws AG, Groen K. Current regulatory guidance on chiral medicinal products: Canada, FRC, Japan and US. Chirality 1994; 6: 72-5
3. Tomaszewski J, Rumore MM. Stereoisomcric drugs: FDA's policy statement and the impact on drug development. Drug Dev Indust Pharm 1994; 20: 119-39
4. Stinson SC. Chiral drugs. Chem Eng News 1992; 70: 41-79
5. McMahon PG, Achecar PA, Murray MJ, et al. The importance of chirality to antihypertensive drug effects. Curr Ther Res Clin Exp 1992; 52: 89-97
6. Serilevy A, West S, Richards WG. Molecular similarity, quantitative chirality, and QSAR for chiral drugs. J Med Chem 1994; 37: 1727-32
7. Walther W, Netscher T. Design and development of chiral drugs for the chromatography ot chiral alcohols. Chirality 1996; 8: 397-401
8. Gorog S, Gazday M. Enantiomeric derivatization for biomedical chromatography. J Chromatogr B-Biomed Appl 1994; 659: 51-84
9. Ariens EJ. Stereochemistry in the analysis of drug action. Part II. Med Res Rev 1987; 7: 367-87
10. Ariens EJ. Implications of the neglect of stereochemistry in pharmacokinetics and clinical pharmacology. Drug Intell Clin Pharm 1987; 21: 827-9
11. Holmstedt B, Frank H, Testa B. Chirality and biological activity. New York: Liss, 1990
12. Walle UK, Pesola GR, Walle T. Stereoselective sulfate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Br J Clin Pharmacol 1993; 35: 413-8
13. Piofrovskij VK, Shvatchko EV, Trnovec T. The use of physiological-based models to simulate enantioselective differences in pharmacokinetics. Methods Find Exp Clin Pharmacol 1994; 16: 263-9
14. Easson LH, Stedman E. Studies on the relationship between chemical constitution and physiological action. 5-Molecular dissymmetry and physiological activity. Biochem J 1993; 27: 1257-66
15. Hayball PJ. Chirality and nonsteroiclal anti-inflammatory drugs. Drugs 1496; 52: 47-58
16. Hutt AJ, Tan SC. Drug chirality and its clinical significance. Drugs 1996; 52: 1-12
17. Lotsch J, Geisslinger G, Mohammadian P, et al. Effects of flurbiprofen enantiomers on pain-related chemosomatosensory evoked-polentials in human subjects. Br J Clin Pharmacol 1995; 40: 339-46
18. Motzer RJ, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995; 13: 1958-65
19. Andrews JE, Ebronmccoy M, Bojic U, et al. Validation of an in vitro teratology system using chiral substances: stereoselective teratogenicity of 4-yn-valproic acid in cultured mouse embryos. Toxicol Appl Pharmacol 1995; 132: 310-6
20. Mcmahon FG, Achecar FA, Murray MJ, et al. The importance of chirality to antihypertensive drug effects. Curr Ther Res 1992; 52: 89-97
21. Ariens FJ, Wuis EW. Bias in pharmacokinetics and clinical pharmacology. Clin Pharmacol Therapeut 1987; 42: 361-3
22. Walle T, Walle UK. Chirality Part 4. Pharmacokinetic parameters obtained with racemate. Trends Pharmacol Sci 1986; 7: 115-58
23. Pendleton RG, Newman DJ, Sherman SS, et al. Effect of propranolol upon the hemoglobin-oxygen dissociation curves. J Pharmacol Exp Ther 1972; 180: 647-50
24. Oski EA, Miller LD, Delivoria-Papadopoulos M, et al. Oxygen affinity in the red cells. Changes induced in vivo by propranolol. Science 1972; 175: 1372-3
25. Campbell RWF, Murray A, Julian DG, Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Br Heart J 1981; 46: 351-7
26. Wilson AG, Brooke OG, Lloyd HF, et al. Mechanism of action of β-adrenergic receptor blocking agents in angina pectoris: comparison ot action of propranolol with dexpropranolol and practolol. BMJ 1969; 4: 399-401
27. Brittain RT, Drew GM, Levy GP. The α-adrenoceplor and β-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anesthetized dogs and in isolated tissues. Br J Pharmacol 1982; 77: 105-14
28. Byrnes EW, McMaster PD, Smith ER, et al. New antiarrhythmic agents. 1. Primary a-amino anihdes. J Med Chem 1979; 22: 1171-6
29. Doenicke A, Kugler J, Mayer M. et al. Influence of racemic ketamine and S-(+)-ketamine on vigilance, performance and wellheing. Anaesthetist 1992;41: 610-8
30. Powell JR, Ambre JJ, Ruo TI. Drug stereochemistry: analytical methods and pharmacology. In: Wainer IW, Drayer DE, editors. New York: Marcel Dekker, Inc., 1988: 245-70
31. Downes H, Perry RS, Ostlund RE, et al. Excitatory effects of barbiturates. J Pharmacol Exp Ther 1970; 175: 692-9
32. Buech HP, Schneider-Affeld F, Rummel W. Stereochemical dependence of pharmacological activity in a series of optically active N-methylated barbiturates. Naunyn Schmiedebergs Arch Pharmacol 1973; 277: 191-8
33. Waddell WJ, Baggett B. Anesthetic and lethal activity in mice of the stercoisomers of 5-ethyl-5-methylbutyl barbituric acid (pentobarbitol). Arch Int Pharmacodyn Therapie 1973; 205: 40-4
34. Ambre JJ, Fisher LJ, Glutethimide intoxication: plasma levels of glutethimide and a metabolite in humans, dogs and rats. Res Comm Chem Pathol Pharmacol 1972; 4: 307-26
35. Ambre JJ, Fisher LJ. Identification and activity of hydroxymetubolite that accumulates in plasma of humans intoxicated with glutethimide. Drug Metab Dispos 1974; 2: 151-8
36. Hansen AR, Ambre JJ, Fischer LJ. Glutethimide poisoning: a metabolite contributes in morbidity and mortality. N Engl J Med 1975; 292: 250-2
37. Hansen AR, Kennedy KA, Ambre JJ, et al. Activity of glutethimide metabolite in human beings. N Engl J Med 1975; 292: 871-3
38. Hansen AR, Kennedy KA, Ambre JJ, et al. Gluthethimide poisoning: a metabolite contributes to morbidity and mortality. N Eng J Med 1975; 292: 250-2
39. Reddy IK, Korlipura VL. Chirality implications on drug actions. US Pharmacist 1995; 20: H20-4
40. Scott AK. Stereoisomers and drug toxicity: the value of single stereoisomer therapy. Drug Saf 1993; 8: 149-59
41. Wilson JL, Nayanar V, Walker JS. The site of antiarthritic action of the kappa-opioid. U-50. 488H, in adjurant arthritis: importance of local administration. Br J Pharmacol 1996: 118: 1754-60
42. Geisslinger G, Schaible HG. New insight into the site and mode of antinociceptive action of flurbiprofen enantiomers. J Clin Pharmacol 1996; 36: 513-20
43. Kharasch ED, Herrmann S, Lahroo R. Ketamine as a probe for medetomidine stereoisomer inhibition of human liver microsomal drug metabolism. Anesthesiology 1992; 77: 1208-14
44. Yang T, Prakash C, Roden DM, et al. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol 1995; 115: 267-74
45. Toldy L, Vargha L, Toth I, et al. Promethazine. I. Acta Chim Acad Sci Hung 1959; 19: 273-5
46. Breckenridge A, Orme M, Wesseling H, et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974; 15: 424-30
47. Palareti G, Legnani C. Warfarin withdrawal: pharmacokinetic-pharmacodynamic consideration. Clin Pharmacokinet 1996; 30: 300-13
48. Satoh K, Yanagisawa T, Taira N. Coronary vasodilator and cardiac effects of optical isomers of verapamil in the dog. J Cardiovasc Pharmacol 1980; 2: 309-18
49. Mehver R, Reynolds JM, Robinson MA, et al. Enantioselective kinetics of verapamil and nonverapamil in isolated perfused rat livers. Pharm Res 1994; 11: 1815-9
50. Barrett AM, Cullum VA. The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br J Pharmacol Chemo 1968; 34: 43-55
51. Boyd GS, Oliver MF. Thyroid hormones and plasma lipids. Br Med Bull 1960; 16: 138-41
52. Arends RHGP, Zhang KY, Levy RH, et al. Stereoselective pharmacokinetics of stiripentol: an explanation for the development of tolerance to anticonvulsant effect. Epilepsy Res 1994; 18: 91-6
53. Graf BM, Vicenzi MN, Martin E, et al. Ketamine has stereospecific effects in the isolated perfused guinea pig heart. Anesthesiology 1995; 82: 1426-37
54. Mathisen LC, Skjelbred P, Skoglund LA, et al. Effect of ketamine. an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 1995; 61: 215-20
55. White PF, Ham J, Way WL, et al. Pharmacology of ketamine isomers in surgical patients. Anesthesiology 1980; 52: 231-9
56. Doenicke A, Angster R, Mayer M, et al. Hemodynamics, plasma-catecholamine and cortisol levels after ketamine racemate and S-(+)-ketamine. Anaesthetist 1992; 41: 597-603
57. Prichard BNC. Combined α- and β-adrenoceptor inhibition in the treatment of hypertension. Drugs 1984; 28: 51-68
58. Hartigango K, Bateman DN, Daly AK, et al. Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther 1996; 60: 89-98
59. Gumbleton M, Forbes BJ. Principles in the absorption, distribution and elimination of pharmaceuticals. Pestic Sci 1994; 42: 223-40
60. Valenzuela C, Snyders DJ, Bennett PB, et al. Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes. Circulation. 1995; 92: 3014-24
61. Wainer IW. Stereoisomers in clinical oncology: why it is important to know what the right and left hands are doing. Ann Oncol 1993; 4: S7-13
62. Laethem ME, Belpaire FM, Wijnant P, et al. Stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil: species differences and influence of endotoxin. Chirality 1995; 7: 616-22
63. Pacifici GM, Desanti C, Mussi A, et al. Interindividual variability in the rate of salbutamol sulfation in the human lung. Eur J Clin Pharmacol 1996; 49: 299-303
64. Eaton EA, Walle UK, Wilson HM, et al. Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol 1996; 41: 201-6
65. Chapman ID, Buchheit KH, Manley P, et al. Active enantiomers may cause adverse effects in asthma. Trends Pharmacol Sci 1992; 13: 231-35
66. Pesola GR, Walle T. Enatiomeric interaction in the sulfate conjugation of the β2-agonist drug albuterol by the human liver. Res Commun Chem Pathol Pharmacol 1992; 75: 125-8
67. Boulton DW, Fawcett JP. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol 1996; 41: 35-40
68. Drayer DE. Pharmacodynamics and pharmacokinetics differences between drug enantiomers in humans: an overview. Clin Pharmacol Ther 1986; 40: 125-33
69. Bourahla A, Martin C, Gimenez F, et al. Stereoselective pharmacokinetics of mefloquine in young children. Eur J Clin Pharmacol 1996; 50: 241-4
70. Walle T, Webb JG, Bagwell EE, et al. Stereoselective delivery and actions of β-receptor antagonists. Biochem Pharmacol 1988; 37: 115-24
71. Fehske KJ, Muller E, Woller U. The location of drug binding sites in human serum albumin. Biochem Pharmacol 1981; 30: 687-92
72. Kristensen K, Blemmer T, Angelo HR, et al. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 1996; 18: 221-7
73. Stagni G, Davis PJ, Ludden TM. Human pharmacokinetics of betaxolol enantiomers. J Pharm Sci 1991; 80: 321-4
74. Zhou HH, Wood AJJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995; 57: 518-24
75. Echizen H, Takahashi H, Nakamura H, et al. Stereoselective disposition and metabolism of disopyramide in pediatric patients. J Pharmacol Exp Ther 1991; 259: 953-60
76. Kharasch ED, Labroo R. Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology 1992; 77: 1201-7
77. Skeith KJ, Russell AS, Jamali F. Ketoprofen pharmacokinetics in the elderly; influence of rheumatic disease, renal function, and dose. J Clin Pharmacol 1993; 33: 1052-9
78. Notterman DA, Drayer DE, Metakis L, et al. Stereoselective renal tubular secretion of quinidine and quinine. Clin Pharmacol Ther 1986; 40: 511-7
79. Echizen H, Vogelgesang B, Eichelbaum M. Effect of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther 1985; 38: 71-6
80. Von Bahr C, Hermansson J, Tawara K. Plasma levels of (+)- and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (±)-propranolol in man. Br J Clin Pharmacol 1982; 14: 79-82
81. Sedman AJ, Gal J, Mastropaolo E, et al. Serum tocainide enantiomer concentrations in human subjects. Br J Clin Pharmacol 1984; 17: 113-5
82. Thomson AB, Murdock G, Pottage A, et al. Pharmacokinetics of (R)- and (S)-tocainide in patients with ventricular arrhythmias. Br J Clin Pharmacol 1986; 21: 149-54
83. Drayer DE. Stereochemistry: analytical methods and pharmacology. In: Wainer IW, Drayer DE, editors. New York: Marcel Dekker, Inc., 1988: 209-25
84. Thijssen HHW, Junssen GMJ, Baars LGM. Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral does of (R)-acenocoumarol and (S)-acenocoumarol. Eur J Clin Pharmacol 1986; 30: 619-23
85. Tucker GT, Lennard MS. Enantiomer-specific pharmacokinetics. Pharmacol Ther 1990; 45: 309-29
86. Drayer DE. Problems in therapeutic drug monitoring: the dilemma of enantiomeric drugs in man. Ther Drug Monit 1988; 10: 1-7
87. McMenany R, Oncley JL. Specific binding of l-tryptophan to serum albumin. J Biol Chem 1958; 233: 1436-47
88. Muller WE, Wollert U. High stereospecificity of the benzodiazepine binding site on human serum albumin. Mol Pharmacol 1975; 11: 52-60
89. Brown NA, Jahnchen E, Muller WE, et al. Optical studies on the mechanism of the interaction of the enantiomers of the anticoagulant drugs phenprocoumon and warfarin with human serum albumin. Mol Pharmacol 1977; 13: 70-9
90. Dayton R Stiller RL, Cook DR, et al. Binding of kelamine to plasma proteins: emphasis on human plasma. Eur J Clin Pharmacol 1983; 24: 825-31
91. 1-acid glycoprolein and albumin. Clin Pharmacol Ther 1983; 34: 718-23
92. Mignot I, Presle N, Lapicque F, et al. Albumin binding sites for etodolac enantiomers. Chirality 1996; 8: 271-80
93. Brocks DR, Jamali F, Russel AF. Stereoselective disposition of etodolac enantiomers in synovial fluid. J Clin Pharmacol 1991; 31: 741-6
94. Muller N, Lapicque F, Monot C, et al. Stereoselective binding of etodolac to human serum albumin. Chirality 1992; 4: 240-6
95. Cayen MN. Racemic mixtures and single stereoisomers: industrial concerns and issues in drug development. Chirality 1991; 3: 94-8
96. Pesola GR, Walle T. Enantiomeric interaction in the sulfate conjugation of the β2-agonist drug albuterol by the human liver. Res Commun Chem Patho Pharmacol 1992; 75: 125-8
97. Brocks DR, Jamali F. Stereochemical aspects pf pharmacotherapy. Pharmacotherapy 1995; 15: 551-64
98. Hansten PD. Drug interactions: clinical significance of drug-drug interactions and drug effects on clinical laboratory results. Philadelphia: Lea and Febiger, 1975
99. Berry, Jamali. Enantiomeric interaction of flurbiprofen in the rat. J Pharm Sci 1989; 78: 632-4
100. Li G, Treiber G, Klotz U. Ibuprofen-cimetidine interaction: stereochemical considerations. Drug Invest 1989; 1: 11-7
101. Wingard LB, Levy G. Prothrombin complex activity produced equieffective doses of (R)-(+)- and (S)-(-)-warfarin in humans. J Pharm Sci 1997; 60: 1790-1
102. Itoh T, Nukushima K, Tstida Y, et al. Stereoselective binding of carbenicillin epimers to human serum albumin. Chirality 1996; 8: 201-6
103. Janiali F. Stereochemically pure drugs: an overview. In: Wainer IW, editor. Drug stereochemistry: analytical methods and pharmacology. 2nd ed. New York: Marcel Dekker, Inc, 1993: 375-84
104. Yacobi A, Levy G. Protein binding of warfarin enantiomers in serum of humans and rats. J Pharmacokinet Biopharm 1977; 5: 123-31
105. Loun B, Hage DS. Chiral separation mechanisms in protein-based HPLC columns. I. Thermodynamic studies of (R)- and (S)-warfarin binding to immobilised human serum albumin. Anal Chem 1994; 66: 381-2
106. Lewis RJ, Trager WF, Chan KK, et al. Warfarin: stereochemical aspects of its metabolism and the interaction wilh phenylbutazone. J Clin Invest 1974; 53: 1607-17
107. Somogyi A, Gugler R. Drug interactions with cimetidine. Clin Pharmacokinet 1982; 7: 23-41
108. Choonara IA, Cholerton S, Haynes BP, et al. Stereoselective interaction between the (R)-enantiomer of warfarin and cimetidine. Br J Clin Pharmacol 1986; 21: 271-7
109. Kunze KL, Eddy AC, Gribaldi M, et al. Metabolic enantiomeric interactions: the inhibition of human S-warfarin-7-hydroxylase by R-warfarin. Chirality 1991; 3: 24-9
110. Niopas I, Toon S, Rowland M. Further insight into the Stereoselective interaction between warfarin and cimetidine in man. Br J Pharmacol 1991; 32: 508-11
111. Zhou HH, Anthony LB, Reden DM, et al. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther 1990; 47: 686-93
112. Birgersdotter UM, Wong W, Turgeon J, et al. Stereoselectivity genetically determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol 1992; 33: 275-80
113. Kroemer HK, Funck-Brentane C, Silberstein DJ, et al. Stercoselective disposition and pharmacological activity of propafenone enantiomers. Circulation 1989; 79: 1068-76
114. Brode E, Muller H, Peltzer O, et al. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. Methods Find Exp Clin Pharmacol 1988; 10: 717-27
115. Kroemer HK, Fischer C, Meese CO, et al. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of mechanism. Mol Pharmacol 1991; 40: 135-42
116. Kroemer HK, Fromm MF, Buhl K, et al. An enantiomer-enantiomer interaction of (S)-propafenone and (R)-propafenone modifies the effect of racemic drug-therapy. Circulation 1994; 89: 2396-400
117. Zily W, Breimer DD and Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolutamide clearance. Eur J Clin Pharmacol 1975; 9: 219-27
118. Caldwell J. Racemates and enantiomers: scientific and regulatory aspects. Chirality 1989; 1: 249-50
119. Abul-Enein HY, Islam MR, Direct HPLC separation of thalidomide enantiomers using cellulose tris-4-methylphenyl benzoate chiral stationary phase. J Liqu Chromatog 1991; 14: 667-73
120. Yashima E. Sahavattanapong P, Okamoto Y. HPLC enantioseparation on cellulose Tris(3,5-dimethylphenylcarbamate) as a chiral stationary phase: influences of pore size of silica gel, coating amount, coating solvent and column temperature on chiral discrimination. Chirality 1996; 8: 446-51
121. Baume B, Fernandez C, Gimenez F, et al. Chirality: pharmacokinetic implications. Part I. Methods of separation of isomers of chiral drugs: application to the determination of their concentration in biological fluids. J Pharm Clinique 1992; 11: 81-94
122. Shaw CJ, Silverman CE, Enantiomeric separation of aminophosphonic acids by capillary electrophoresis. Chiralily 1996; 8: 84-7
123. Ward TJ, Dann III C, Brown AP. Separation of enantiomers using vancomycin in a countercurrent process by suppression of electro-osmosis. Chirality 1996; 8: 77-83
124. Dalgliesh CE. Optical resolution of aromatic amino acids on paper chromatography. J Chem Soc 1952; 137: 3940-2
125. Wainer IW, Caldwell J. The 1996 Chirality debate. Chirality 1997; 9: 95
126. Booth TD, Wahnon D, Wainer IW. Is chiral recognition a three-point process? Chirality 1997; 9: 96-8
127. Davankov VA. The nature of chiral recognition: is chiral a three-point interaction? Chirality 1997; 9: 99-102
128. Ariens EJ. Stereochemistry. a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 1984; 26: 663-8
129. White PF, Schutter J, Shafer A, et al. Comparative Pharmacology of the ketamine isomers. Br J Anaesth 1985; 57: 197-203
130. Lewis RJ, Trager WF. Warfarin metabolism in man: identification of metabolites in urine. J Clin Invest 1970; 49: 907-13
131. Lewis RJ, Trager WF, Chan KK, et al. Warfarin: stereochemical aspects of its metabolism and interaction with phenylbutazone. J Clin Invest 1974; 53: 1607-17
132. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs 1983; 25: 610-20
133. Eliel EL. Stereochemistry of carbon compounds. New York: McGraw-Hill, 1962
134. Testa B. The Chromatographic analysis of enantiomers in drug metabolism studies. Xenobiotica 1986; 16: 265-79
135. Carabaza A, Suesa N, Tost D, et al. Stereoselective metabolicpathways of ketoprofen in the rat: incorporation into triacylglycerols and enantiomeric inversion. Chirality 1996; 8: 163-72